<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0"><channel><title>medsurfnews.com</title><link>http://www.medsurfnews.com</link><description>Le ultime risorse da Medsurfnews.com</description><language>it</language><pubDate></pubDate><copyright>Healthware.it</copyright><webmaster>francesco.raimondo@healthware.it</webmaster><image><title>Medsurfnews Rss</title><url>http://www.medsurfnews.com/images/logo.jpg</url><link>http://www.medsurfnews.com</link></image>
	
	
	
<item>
<category>Farmacologia</category>
<title>Romiplostim for Immune Thrombocytopenia</title>
<link>http://www.medsurfnews.com/contents/it/7257/display/romiplostim-for-immune-thrombocytopenia.aspx</link>
<description><![CDATA[In the treatment of thrombocytopenic purpura, the used drugs are the ones capable to stimulate platelet production, even if these products, even obtaining an increase in the number of platelets, are not often capable to reach clinically significant results, antagonized as they are by the increased platelet destruction, typical of purpura.]]></description>
<pubDate>Mon, 7 May 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>Dabigatran in Atrial Fibrillation</title>
<link>http://www.medsurfnews.com/contents/it/7258/display/dabigatran-in-atrial-fibrillation.aspx</link>
<description><![CDATA[Dabigatran is an inhibitor of thrombin, authorized for its use in the prevention of stroke in patients with atrial fibrillation, showing the efficacy and the safety of warfarin but with some advantages compared to this one. The great problem of dabigatran is however represented by the cost-efficacy relation.]]></description>
<pubDate>Mon, 7 May 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>Fondaparinux in Superficial Phlebothrombosis</title>
<link>http://www.medsurfnews.com/contents/it/7103/display/fondaparinux-in-superficial-phlebothrombosis.aspx</link>
<description><![CDATA[In the treatment of superficial non-complicated venous thrombosis in general, the use of an anticoagulation therapy is not advised, but in this international double-blinded trial, sponsored by pharmaceutical industry, 3002 patients with superficial phlebothrombosis have been randomized to receive fondaparinux (an Xa-factor inhibitor) or placebo, for 45 days.]]></description>
<pubDate>Mon, 5 Mar 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>Glucosamine and Chondroitin in Hip or Knee Osteoarthritis</title>
<link>http://www.medsurfnews.com/contents/it/7038/display/glucosamine-and-chondroitin-in-hip-or-knee-osteoarthritis.aspx</link>
<description><![CDATA[The results of the trials analyzing the use of glucosamine and chondroitin in osteoarthritis are not univocal: one of the widest trials has found no benefits with the use of these drugs, alone or in association (NEJM 2006 Feb 23; 354: 795-808 - NEJM 2006 Feb 23; 354: 858-860). Now, a meta-analysis has been performed on 10 randomized trials where 3800 patients (68% women; averagely 62 years of age) with hip or knee osteoarthritis have been treated with one or both drugs or placebo; all patients have been assessed as to joint pain – someone also through X-ray – during the follow-up lasted from 1 to 36 months. ]]></description>
<pubDate>Mon, 13 Feb 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>Tiotropium in Non-Controlled Asthma</title>
<link>http://www.medsurfnews.com/contents/it/6997/display/tiotropium-in-non-controlled-asthma.aspx</link>
<description><![CDATA[When the administration of inhaled corticosteroids is not sufficient to control asthma symptoms, guidelines suggest the increase in cortisone dose or the adding of a long-acting beta-agonist, while anticholinergic drugs are first-choice drugs in patients with COPD. So, researchers have wondered whether these last products can obtain some benefits also in asthma: with a double-blinded, randomized trial, sponsored by NIH, with a crossover, 210 adults with asthma non-controlled by the usual therapy, treated with inhaled beclometasone (80 μg twice a day), have been treated in sequence with the adding of salmeterol, then with the adding of an anticholinergic (tiotropium) or with a double cortisone dose.]]></description>
<pubDate>Mon, 23 Jan 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>Milnacipran in Fibromyalgia</title>
<link>http://www.medsurfnews.com/contents/it/6956/display/milnacipran-in-fibromyalgia.aspx</link>
<description><![CDATA[In 2009, in the USA, the use of milnacipram (a selective serotonin-norepinephrine reuptake inhibitor) was approved for the treatment of fibromyalgia. With a trial sponsored by pharmaceutical industry, 1025 patients affected by this disease for an average period of 11 years have been treated with milnacipram or placebo.]]></description>
<pubDate>Mon, 9 Jan 2012 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>Sibutramine and Cardiovascular Events</title>
<link>http://www.medsurfnews.com/contents/it/6864/display/sibutramine-and-cardiovascular-events.aspx</link>
<description><![CDATA[Weight loss is fundamental for the prevention of cardiovascular events, so trials to find effective solutions to overweight and obesity are more and more frequently performed. In this trial, sponsored by pharmaceutical industry, over 10,000 subjects with an excess of weight and with known cardiovascular risk factors or with type 2 diabetes and at least another risk factor have been collected. ]]></description>
<pubDate>Mon, 21 Nov 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>Bupropion and Naltrexone to Lose Weight</title>
<link>http://www.medsurfnews.com/contents/it/6865/display/bupropion-and-naltrexone-to-lose-weight.aspx</link>
<description><![CDATA[In the equipment of drugs to obtain a weight loss, there are some products which really produce a weight loss but which are not used for this reason because of their heavy side effects, such as, for example, rimonabant (an antagonist of cannabinoid receptors, recently retired from the market) and, partly, sibutramine. ]]></description>
<pubDate>Mon, 21 Nov 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>35 innovative new drugs approved in fiscal year 2011</title>
<link>http://www.medsurfnews.com/contents/it/6840/display/35-innovative-new-drugs-approved-in-fiscal-year-2011.aspx</link>
<description><![CDATA[Over the past 12 months, the U.S. Food and Drug Administration approved 35 new medicines. This is among the highest number of approvals in the past decade, surpassed only by 2009 (37). Many of the drugs are important advances for patients, including: two new treatments for hepatitis C; a drug for late-stage prostate cancer; the first new drug for Hodgkin’s lymphoma in 30 years; and the first new drug for lupus in 50 years.
]]></description>
<pubDate>Mon, 7 Nov 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	
<item>
<category>Farmacologia</category>
<title>Drug-Related Hyperkaliemia</title>
<link>http://www.medsurfnews.com/contents/it/6762/display/drug-related-hyperkaliemia.aspx</link>
<description><![CDATA[The use of drugs interfering with the rennin-angiotensin system has become wider and wider, in recent years, with the marketing of ACE-inhibitors before and of ARB (sartans) afterwards. With such a high number it is easy to discover the birth of new interactions between drugs. Knowing that hyperkaliemia has been associated with the use of ACE-inhibitors and trimethoprim, a case-control trial has been performed in Toronto among subjects ≥ 66 years of age under continuative treatment with drugs inhibiting rennin-angiotensin system and administered with an antibiotic.]]></description>
<pubDate>Mon, 10 Oct 2011 12:00:00 +0200</pubDate>
</item>	
	
	
	
	
	</channel></rss>
	



